Sanofi (SNY) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Sanofi (NASDAQ: SNY) in the last few weeks:

• 12/22/2025 – Sanofi had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Sanofi had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – Sanofi had its “buy” rating reaffirmed by analysts at HSBC Holdings plc.
• 12/9/2025 – Sanofi was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.
• 12/8/2025 – Sanofi had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
• 12/1/2025 – Sanofi had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Sanofi had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Sanofi had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/5/2025 – Sanofi had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/27/2025 – Sanofi had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc..

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.